AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02786251 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cold exposure
Description: During cold exposure intervention, we will use an individualized cold exposure protocol above the individual shivering threshold of each participant using liquid condition garments and a temperature controlled room.
Study NCT01911559 — intervention group
Intervention type: DEVICE
Intervention: standing-frame
Study NCT02298842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelets stored in InterSol
Description: A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. Following each blood collection, Platelet Additive Solution (PAS), InterSol, will be added to the platelet product to prepare the final product for 7 day storage. The entire procedure is painless and should take 90 to 120 minutes and the subjects will have two collections within 6-8 days of each other.
Study NCT02298842 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Platelets stored in Plasma
Description: A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. During the collection, plasma collected from the donor will be added to the platelet product to prepare the final product for 7 day storage. The entire procedure is painless and should take 90 to 120 minutes and the subjects will have two collections within 6-8 days of each other.
Study NCT03258866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: given with a fixed dose of 100 mg administered as an intravenous infusion weekly (on day 1, 8, 15 and 22)
Study NCT03258866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: given with a single dose of 375mg/m2
Study NCT01018550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 853
Description: AMG 853 5 mg (BID)
Study NCT02786251 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exposure to thermoneutral conditions
Description: For the thermoneutral conditions intervention, subjects will be exposed to thermoneutral conditions (\~26-28°C).
Study NCT04498611 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: contrast-enhanced breast MRI
Description: Contrast-enhanced MRI will be performed on patients diagnosed with ductal carcinoma in-situ (DCIS) by preoperative biopsy.
Study NCT00523003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high protein
Description: 2.2 g protein/kg of LBM per day
Study NCT00523003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: standard protein
Description: 1.1 g protein/kg LBM/day standard protein diet
Study NCT03012425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Study NCT03012425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Study NCT01018550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 853
Description: AMG 853 200 mg (QD)
Study NCT01018550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 853
Description: AMG 853 25 mg (BID)
Study NCT01018550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 853
Description: AMG 853 100 mg (BID)
Study NCT03012425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires
Study NCT03012425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diurnal Cortisol
Description: saliva test
Study NCT01018550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04286607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical roflumilast
Description: Active treatment
Study NCT03121677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized tumor vaccine
Description: * Cycle 12 vaccine administration is optional~* The peptides comprising the vaccine are reconstituted in up to 4 pools with 5 peptides per pool (A, B, C, and D) . At each vaccination time point, each of the up to four pools will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous injection.
Study NCT03121677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: -The personalized tumor vaccine will be co-administered with poly-ICLC.
Study NCT03121677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: -Nivolumab will be administered at a dose of 240 mg intravenously
Study NCT03121677 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draws
Description: -Time of biopsy, during the pre-treatment check (any time before cycle 1 day 1), Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 6 Day 1, Cycle 12 Day 1, Time of response, and Time of progression or relapse
Study NCT03121677 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: * Prior to the initiation of treatment and up to five days prior to treatment on cycle 6 day 1, patients will undergo apheresis according to standard institutional procedures for non-mobilized collection.~* Peripheral blood leukocytes will be cryopreserved for later assessment for the presence of T-cells that recognize tumor specific mutant antigens and immunophenotype, and the presence of other lymphocytes or regulatory populations.
Study NCT03121677 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: -Other anti-CD20 mAb treatment can be used
Study NCT03121677 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: -Biopsies on lymph node or extranodal site(s) are to be obtained at: screening (only after the patient is deemed eligible; during cycle 2 (after treatment on C2D15 and prior to treatment on C3D1); disease relapse or progression (if this occurs)
Study NCT03455920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical nurse (supernurse) evaluation
Description: The first evaluation of the patient refered to the sleep clinic will be performed by the clinical nurse then discussed with the pulmonologist in charge.
Study NCT03455920 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonologist evaluation
Description: The first evaluation of the patient refered to the sleep clinic will be performed only by the pulmonologist.
Study NCT00770289 — intervention group
Intervention type: OTHER
Intervention: Cohort
Description: Cohort (Patients diagnosed with MDD who are either changing treatment or have never received treatment).
Study NCT01128257 — intervention group
Intervention type: DRUG
Intervention: alendronate
Description: As prescribed by physician
Study NCT01128257 — intervention group
Intervention type: DRUG
Intervention: ibandronate [Bonviva/Boniva]
Description: As prescribed by physician
Study NCT02733991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniMed™640G and Suspend before low
Description: All enrolled subjects will start a run in phase, receive training and start pump therapy with the MiniMed™640G insulin pump and usage of blinded Continuous Glucose Monitoring. Eligible subjects that meet the randomization criteria assessed after the running phase will be randomized into the treatment or control arm. Treatment Arm: training and start of Sensor Augmented Pump therapy with Suspend before Low feature of SmartGuard turned ON.~Control Arm: continuation of pump therapy alone with blinded continuous glucose monitoring for a total of 6 weeks during the treatment phase.
Study NCT02733991 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MiniMed™640G
Description: Control Arm: continuation of pump therapy alone with blinded continuous glucose monitoring for a total of 6 weeks.
Study NCT04447261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356225
Description: BI 1356225
Study NCT04447261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01588808 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Immobilization
Description: Immobilization with protein (elderlY), immobilization without protein (elderly and young)
Study NCT01588808 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Immobilization
Description: Immobilization with protein (elderlY), immobilization without protein (elderly and young)
Study NCT02268864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir 150 mg oral capsule will be administered once daily for 12 or 24 weeks.
Study NCT02268864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Daclatasvir 60 mg oral tablet will be administered once daily for 12 or 24 weeks.
Study NCT04162015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab 360 mg
Study NCT04162015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m\^2
Study NCT04162015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin or Carboplatin
Description: cisplatin 75 mg/m2 or carboplatin AUC=5
Study NCT01096225 — intervention group
Intervention type: BIOLOGICAL
Intervention: split-virion, H1N1 vaccine of 15 μg
Description: split-virion inactivated S-OIV vaccine of 15 μg on day 0 and 21.
Study NCT01657045 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JVS-100 or placebo
Description: Injections will be delivered depending on sternal incision length.
Study NCT02377466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retosiban IV infusion
Description: Retosiban for IV administration will be supplied as solution for infusion, consisting of a clear colorless solution of retosiban at a concentration of 15 milligram per milliliter (mg/mL).
Study NCT02377466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV infusion
Description: 0.9% NaCl matched for the retosiban loading dose and continuous infusion rates
Study NCT03894579 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Study Product: SNK01
Description: SNK01 administered using an intravenous line (IV) to all patients at weeks 1, 2, 3, and 4
Study NCT01485770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ADX-N05
Description: 150 mg once a day for seven days followed by 300 mg once a day for seven days
Study NCT01485770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-N05
Description: 150 mg once a day for seven days followed by 300 mg once a day for seven days
Study NCT01485770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ADX-N05 once a day for 2 consecutive weeks
Study NCT01485770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match ADX-N05 once a day for 2 consecutive weeks
Study NCT01860651 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-monitoring
Description: During the E-health intervention, symptoms and FC are monitored closely through the web-program and treatment will be initiated by symptoms and elevated FC.
Study NCT02366520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: handheld mirror
Description: The child may see the dental treatments that are conducted in his or her mouth by a handheld mirror.
Study NCT03791840 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound evaluation
Description: High-frequency ultrasound is used to detected the lymph node metastasis in vivo and vitro. The lymph node number, morphology and elastographic parameters are collected in the patients and in fresh lymph node specimens.
Study NCT00005937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin
Description: Antithymocyte globulin (ATG) intravenous infusion: 40mg/kg/day. Infusion over 6 hours on day 1-4.
Study NCT04023552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQJ230
Description: TQJ230 80 mg injected monthly administered subcutaneously
Study NCT04023552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match TQJ230 prefilled syringe to be injected subcutaneously
Study NCT01678573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: abiraterone acetate
Description: 250 mg/day tablet administered orally on Day 1 of each treatment period.
Study NCT01678573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: abiraterone acetate
Description: 500 mg/day tablets administered orally on Day 1 of each treatment period.
Study NCT01678573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: abiraterone acetate
Description: 1000 mg/day tablets administered orally on Day 1 of each treatment period.
Study NCT02466958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levomilnacipran
Description: antidepressant
Study NCT02466958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: an inactive drug
Study NCT02187276 — intervention group
Intervention type: DRUG
Intervention: cholinesterase inhibitors
Description: The first group received donepezil (5 or 10 mg) the second group received galantamine (16 or 24 mg) The third group received rivastigmine (3 or 4,5 or 6 mg BID) according to the treating physician.
Study NCT04318483 — intervention group
Intervention type: OTHER
Intervention: survey
Description: parents' telephone interview to collect medical history
Study NCT04024813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seladelpar
Description: Capsule(s) administered orally once daily
Study NCT04024813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match Seladelpar
Description: Capsule(s) administered orally once daily
Study NCT03448393 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/CD22 CAR T-Cells
Description: CD19/CD22 cells will be infused on Day 0 after induction chemotherapy regimen.
Study NCT03448393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is administered as an IV infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on BSA (25 mg/m2/dose)
Study NCT03448393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion on Day -2.
Study NCT01364883 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination Schedule One
Description: Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
Study NCT01364883 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination Schedule Two
Description: Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
Study NCT01364883 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination Schedule Three
Description: Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
Study NCT01364883 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination Schedule Four
Description: Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
Study NCT01364883 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination Schedule Five
Description: Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
Study NCT01364883 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination Schedule Six
Description: Intramuscular injection of 5x10\^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10\^8 pfu of MVA ME-TRAP
Study NCT01364883 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination Schedule Seven
Description: AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W8, AdCh63 ME-TRAP boost W16, MVA ME-TRAP boost W24
Study NCT00774839 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient Interview
Description: The patient will participate in a semistructured interview conducted by a trained staff member and designed to last approximately 45 minutes. All interviews will take place at least 4 months into or up to 7 months after the end of the treatment, if possible and will be scheduled to occur at the time of the chemotherapy infusion, or at another time at the care facility when it is convenient for the patient. If the patient is not scheduled or chooses not to be at the care facility within a time frame that fits the study parameters, the patient may opt to be interviewed at another location, including the patient's home.
Study NCT00005937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine (CsA) intravenous infusion: 5mg/kg. Infusion on day 14 administered twice a day.
Study NCT03178981 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use electronic cigarette or smoke conventional cigarette
Description: Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period
Study NCT03178981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use electronic cigarette or smoke conventional cigarette
Description: Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period
Study NCT00764153 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bipolar hemiarthroplasty
Description: Lateral approach. FWB.
Study NCT00764153 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Internal fixation
Description: Fluoroscopic Control. Percutaneous. FWB. Two parallel screws (Olmed)
Study NCT01020851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tailored intervention
Description: 6 monthly telephone calls focusing on diet, medication and exercise adherence using the framework of the transtheoretical model
Study NCT01020851 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: attention placebo
Description: 6 monthly telephone-delivered sessions focusing on general health topics
Study NCT00742001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mirasol System for Whole Blood.
Description: Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects
Study NCT02312895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: The therapist will locate the involved segment using passive accessory intervertebral movements. The segment will be localized to the level, which provokes the patient's symptoms most easily, and this segment will be determined to be the involved level. Once this level has been identified, the therapist will compare central glides over the spinous process or a unilateral glide over the facet joint to determine which is more provocative. Whichever is most provocative will be the location of the treatment. The therapist will provide 3 bouts lasting 45 seconds just easing into the patient's symptoms at the most provocative level with approximately 45 seconds rest between each bout.
Study NCT02312895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling involves inserting a dry, mono-filament needle through the skin and into an area of symptomatic soft tissue. The two-inch needles will be placed segmentally and into the lower extremities following peripheral nerve patterning by the treating physical therapist. Following initial penetration into the skin over the tender area, the therapist carefully advances the needle into the tissue below the skin. After the needle has reached the desired depth, the therapist will insert the subsequent needles. Needles will be placed along the segmental levels of the lumbar spine above and below the tender area identified and into the lower extremity in areas that correlate with a peripheral nerve map. Needles will remain in the tissue for up to 5 minutes, removed, and appropriately disposed of.
Study NCT02312895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Program
Description: A home exercise program will be given to each subject to be completed in the clinic and at home 1x/day. The exercises will consist of active range of motion exercises and core stabilization exercises. The program is standardized for all subjects.
Study NCT03187262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab is a monoclonal human antibody. Daratumumab has shown the ability to slow or stop the growth of cells that have CD38 on the cell surface when tested in laboratories
Study NCT02277301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mellow Babies
Description: Mellow Babies is an intervention designed for mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.